[go: up one dir, main page]

WO2020055360A3 - The parenteral composition comprising carfilzomib - Google Patents

The parenteral composition comprising carfilzomib Download PDF

Info

Publication number
WO2020055360A3
WO2020055360A3 PCT/TR2019/050580 TR2019050580W WO2020055360A3 WO 2020055360 A3 WO2020055360 A3 WO 2020055360A3 TR 2019050580 W TR2019050580 W TR 2019050580W WO 2020055360 A3 WO2020055360 A3 WO 2020055360A3
Authority
WO
WIPO (PCT)
Prior art keywords
carfilzomib
parenteral composition
composition
parenteral
furthermore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050580
Other languages
French (fr)
Other versions
WO2020055360A2 (en
Inventor
Ali Turkyilmaz
Irem Yenice
Ali Ihsan SECKIN
Yuksel TOPALOGLU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Publication of WO2020055360A2 publication Critical patent/WO2020055360A2/en
Publication of WO2020055360A3 publication Critical patent/WO2020055360A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof. Furthermore, the composition is obtained using an effective process.
PCT/TR2019/050580 2018-08-10 2019-07-16 The parenteral composition comprising carfilzomib Ceased WO2020055360A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/11693 2018-08-10
TR201811693 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020055360A2 WO2020055360A2 (en) 2020-03-19
WO2020055360A3 true WO2020055360A3 (en) 2020-06-04

Family

ID=69777254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050580 Ceased WO2020055360A2 (en) 2018-08-10 2019-07-16 The parenteral composition comprising carfilzomib

Country Status (1)

Country Link
WO (1) WO2020055360A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202316194D0 (en) * 2023-10-23 2023-12-06 Arecor Ltd Novel compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162352A1 (en) * 2007-12-21 2009-06-25 Michael Adler Antibody formulation
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
US20180117054A1 (en) * 2016-10-29 2018-05-03 Cipla Limited Stable carfilzomib formulations
WO2018138556A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Non-aqueous carfilzomib compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162352A1 (en) * 2007-12-21 2009-06-25 Michael Adler Antibody formulation
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
US20180117054A1 (en) * 2016-10-29 2018-05-03 Cipla Limited Stable carfilzomib formulations
WO2018138556A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Non-aqueous carfilzomib compositions

Also Published As

Publication number Publication date
WO2020055360A2 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
SG10201804852XA (en) Regularized parameter adaptation
MX2022001829A (en) Process of making cftr modulators.
NZ730724A (en) Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2017003518A (en) Sgc stimulators.
CA3139411A1 (en) Novel peptide compound or pharmaceutically acceptable salt thereof
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
CA3048452C (en) Processes for preparing glycoprotein-drug conjugates
ZA202007737B (en) Pentacyclic compound
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2019001228A (en) Production method for pyrazole-amide compound.
PH12018500999A1 (en) Sodium channel blocker
WO2019109067A3 (en) Creatine prodrugs, compositions and methods of use thereof
PH12019550154B1 (en) Azetidine derivative
MX2019004182A (en) Process for the manufacture of 2,6-dimethyl-5-hepten-1-al.
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2016013439A (en) Solid forms of a pharmaceutically active compound.
WO2020055360A3 (en) The parenteral composition comprising carfilzomib
PH12019501977A1 (en) Additive composition for ground improvement
WO2019122455A8 (en) Process for preparation of amorphous functionalized olefin copolymer
MX2019000984A (en) Process for the preparation of indanones.
AU2019248350A8 (en) Process for making sarecycline hydrochloride
WO2020128020A3 (en) Process for preparing 2-alkoxy-4-amino-5-methyl-pyridines and/or 2-alkoxy-4-alkylamino-5-methyl-pyridines
WO2021107514A3 (en) Method for preparing lifitegrast
MX2021012690A (en) Crystalline forms and methods of producing crystalline forms of a compound.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19860518

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19860518

Country of ref document: EP

Kind code of ref document: A2